Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cang-ai Volatile Oil (CAVO) is a traditional Chinese medicine (TCM) aromatic preparation developed by researchers including Dongdong Qin at the Yunnan University of Chinese Medicine for the treatment of depression. It is a complex mixture of volatile oils extracted from ten Chinese aromatic herbs, including *Atractylodes lancea*, *Agastache rugosa*, and *Syzygium aromaticum*. The preparation is administered via inhalation and contains active compounds such as eugenol, 1,8-cineole, and patchouli alcohol. CAVO's antidepressant mechanism involves the regulation of dopamine and serotonin metabolism, modulation of the indoleamine 2,3-dioxygenase (IDO)-mediated tryptophan degradation pathway, and inhibition of neuroinflammation by suppressing microglia activation. It is currently being evaluated in clinical studies using functional near-infrared spectroscopy (fNIRS) to assess changes in cortical excitability and brain functional connectivity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cang-ai Volatile Oil.